FDA 已授予 Lundbeck 的试验药物 amlenetug 快速通道资格，以进一步审查其作为多系统萎缩 (MSA) 患者的潜在新疗法的可能性。Amlenetug 旨在与细胞外 α-突触核蛋白的主要形式结合，从而阻止其吸收并抑制聚集。

Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...

Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the US Food and Drug Administration (FDA) as a potential treatment for multiple system atrophy (MSA). This ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Lundbeck has received the US Food and Drug Administration’s (FDA) fast track designation for its investigational drug amlenetug, a potential treatment for multiple system atrophy (MSA).

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...